Dignify Therapeutics, a biotechnology company dedicated to restoring voluntary bowel and bladder function in patients with ...

Fintel reports that on February 13, 2025, UBS initiated coverage of Celldex Therapeutics (NasdaqCM:CLDX) with a Buy ...

Standard Chartered Bank’s recent Market Outlook event has received resounding praise from clients, with many hailing it as ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.86, a high estimate of $14.00, ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Q4 2024 Earnings Call Transcript February 7, 2025 Iterum Therapeutics plc beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.24. Operator: Hello, everyone. And welcome to the ...

BOSTON, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel ...

LAVA Therapeutics (NASDAQ:LVTX – Get Free Report)’s share price traded down 4.6% during mid-day trading on Wednesday . The stock traded as low as $0.93 and last traded at $0.94. 38,737 shares changed ...

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...